Case Report Ana Carolina Cardoso

Slides:



Advertisements
Similar presentations
FibroTest in the diagnosis of HBV
Advertisements

FibroMax in the most common liver diseases
Non invasive fibrosis markers and/or liver biopsy
Is Liver Biopsy the Gold Standard?
Patrick MARCELLIN. THE CHALLENGE OF TREATING NON RESPONDERS Patrick Marcellin Service d’Hépatologie and INSERM CRB3 Hôpital Beaujon, Clichy University.
Diabetes Mellitus and Non- Alcoholic Fatty Liver Diseas
Updates in Treatment of Hepatitis C Gene LeSage, MD, FACP, AGAF.
Hcv infection and management in advanced liver disease
Alfredo ALBERTI. How to predict outcome in hepatitis C patients Alfredo Alberti Department of Clinical and Experimental Medicine Venetian Institute of.
Optimal therapy in genotype 2 and 3 patients Antonio Craxì Liver & GI Unit, Di.Bi.M.I.S., University of Palermo, Italy
Paul Calès Conflict of interest: FibroMeter
Francesco NEGRO. Steatosis and Chronic Hepatitis C: liaisons dangéreuses? Francesco Negro Unité de Viropathologie Centre Médical Universitaire Genève.
Michel BEAUGRAND.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Non-Invasive Testing for Liver Fibrosis John Scott, MD, MSc Associate Professor, University of Washington.
Liver Fibrosis Are Non-invasive markers sufficient? William Rosenberg Prof of Hepatology University of Southampton CSO iQur Limited; Consultant to Bayer.
Nezam AFDHAL. Initial Presentation  47-year-old white male  Ex-IVDU 20 years ago  Alcohol >20 g/day for 8 years, none for 18 years  Asymptomatic apart.
How to manage non responders Lawrence Serfaty Service d’Hépatologie, UMR S 893 Hôpital Saint-Antoine, UPMC, Paris Clinical case 1.
TWH LIVER CENTRE UHN centre of excellence Liver issues for the Rhuematologist David Wong, MD University of Toronto Disclosures (last.
 During his annual physical in Dec 2007, Mr. A, a 42 y old pilot, presented with elevated liver enzymes and positive antibodies to HCV.  He had no symptoms.
Approach to medical liver biopsies Dr Behrang Mozayani Consultant Histopathologist Southmead hospital Bristol.
How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.
Deranged LFTs Pathways A H Mohsen Dr A H Mohsen MD (KCL), MRCP, DTM&H Consultant Gastroenterologist.
International Congress Highlights 2004 Clinical Update in GI disease Portal Hypertension P. Michielsen University of Antwerp
Management of side effects Cirrhotic on telaprevir Vincent LEROY Clinique Universitaire d’Hépato-Gastroentérologie INSERM U823 CHU de Grenoble.
FT in diagnostic of HCV FibroTest in the diagnosis of HCV Publications on diagnostic performance.
FT in prognostic of HBV FibroTest: predictive value in HBV.
Alessio Aghemo First Division of Gastroenterology Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico Università degli Studi di Milano 5 th Paris.
Evaluating the Patient With Abnormal Liver Tests-2 פרופ ' צבי אקרמן מבית חולים הדסה הר הצופים.
Maria Buti Hospital General Universitario Vall Hebron Barcelona-. Spain Relapser or Non Responder? Chronic Hepatitis C.
How to manage G1 relapsers and non-responders George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal.
5 th Paris Hepatitis Congress Workshop 30/1/2012 Managing complications of DAAs: Case 1 Dr Samuel S. Lee University of Calgary.
FT in diagnostic of HBV Analytical & pre-analytical variability FibroTest and FibroMax.
Progressive histological liver improvement after sustained virological response to therapy in HCV / HIV coinfected patients. Jose L. Casado,
Clinical case Laurent CASTERA 5th PHC, Paris, January Service d’Hépatologie Hôpital Beaujon, Université Paris-7, Clichy, France.
 Treatment regimens –Co-formulated ombitasvir (OBV)/paritaprevir (PTV)/rironavir (r) : 25/150/100 mg QD = 2 tablets –Dasabuvir (DSV) : 250 mg bid  Objective.
ALLY-3  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI DCV 60 mg qd + SOF 400 mg qd Not randomised Open-label ALLY-3 Study: DCV + SOF for.
OBV/PTV/r + DSV Open label Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 1,000 IU/ml Chronic kidney disease with eGFR < 30 ml/min/1.73m 2.
 Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, next observation carried backward DCV + SOF + RBV Randomised* 1:1 Open-label ALLY-3+ study: DCV.
Evaluation of risk for esophageal varices by transient elastometry in patients with HIV and HCV infection and liver cirrhosis M.K. Mausolf 1, M. Berger.
Non-Invasive Liver Testing
Nonalcoholic Fatty Liver Disease / Nonalcoholic Steatohepatitis 소화기내과 R3 신아리 1.
Henry Masur, MD Bethesda, Maryland
No cirrhosis or compensated cirrhosis * No HBV or HIV coinfection
Interpreting Your Test Results
Design Randomisation 1 : 1 Double-blind W8 W12
Predictor factors associated with liver fibrosis and steatosis by transient elastography in HIV mono-infected patients under long-term combined antiretroviral.
New HCV reimbursement criteria
Daclatasvir + Sofosbuvir in Genotype 3 ALLY-3 Study
Design No randomisation Open-label W12 W years HCV genotype 1
ARV-trial.com C-CREST study, Part B: uprifosbuvir (MK-3682)/GZR/ruzasvir (MK-8408) fixed-dose combination + RBV for genotypes 1, 2 and 3 - Phase II Randomisation.
Volume 46, Issue 3, Pages (March 2007)
METAVIR F3-F4 criteria consensus
4th IAS Conference , Sydney, Australia, July 2007
Creatinine clearance ≥ 50 ml/min No HBV or HIV co-infection
Phase 3 Treatment-Naïve and Treatment-Experienced
ARV-trial.com RUBY-I Study, cohort 2: ombitasvir/paritaprevir/ritonavir + dasabuvir + RBV for HCV genotype 1 with renal impairment Design Open label W12.
University of Medicine and Pharmacy “Carol Davila”, Bucharest
New HCV reimbursement criteria
LEAGUE-1 study: daclatasvir + SMV + RBV for genotype 1
HIV infection is an independent risk factor for liver steatosis: A study in HIV mono-infected patients compared to uninfected paired controls and associated.
Phase 3 Treatment-Naïve and Treatment-Experienced
Clinical outcome after SVR: ANRS CO22 HEPATHER
ARV-trial.com C-CREST study, Part B: uprifosbuvir (MK-3682)/GZR/ruzasvir (MK-8408) fixed-dose combination + RBV for genotypes 1, 2 and 3 - Phase II Randomisation.
Non-invasive evaluation of liver fibrosis using transient elastography
Selonsertib in NASH: phase 2
Laurent Castera, Mireen Friedrich-Rust, Rohit Loomba  Gastroenterology 
GS-9674 in NASH: a phase 2 study
ENDURANCE-4 Study: glecaprevir/pibrentasvir in genotype 4, 5 or 6
Validation of serological biomarkers for detection of non-alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV.
Presentation transcript:

Case Report Ana Carolina Cardoso Hôpital Beaujon – Universite Paris VII - France Hospital Universitario da Universidade Federal do Rio de Janeiro - Brasil

Case Report 57 years old, male 2004: diagnosis of HCV infection Contamination: unknown Genotype 3a, Viral Load: 1 200 000 IU/mL BMI: 28, DM No excessive alcohol intake and tobacco use

Case Report Liver biopsy (2005): A1F1 (METAVIR) Treatment (2005): PEG INF / RBV – NR Poor tolerance Follow-up / not retreated

Case Report Platelets 170 G/L PT 85 % ALT 102 IU/l AST 93 IU/l GGT 220 IU/L BMI: 32 January / 2011 Liver Biopsy ?

Case Report January / 2011 FibroScan® – 11.2 kPa

Case Report January / 2011 FibroScan® – 11.2 kPa

Liver Fibrosis (METAVIR) Case Report FibroScan® (kPa) 8.8 9.6 14.6 Liver Fibrosis (METAVIR) Previous studies showed that ls values strongly correlate with Metavir score for hepatitis c as seen in this slide. The studies determine that ls cut offs for f1/f2/f3/f4 stages are 7.1, 9.5 and 12.5 F0-F1 F2 F3 F4 Ziol et al, Hepatology 2005 7

Case Report – Question 1 FibroScan® is correct ? Liver Biopsy ? What could we conclude ? FibroScan® is correct ? Liver Biopsy ? Another non invasive test ?

Case Report January / 2011 FibroTest – 0.80

Case Report January / 2010 Fibrotest 0.75-1.00 F4 0.73-0.74 F3-F4 Equivalent METAVIR 0.75-1.00 F4 0.73-0.74 F3-F4 0.59-0.72 F3 0.49-0.58 F2 0.32-0.48 F1-F2 0.28-0.31 F1 0.22-0.27 F0-F1 0.00-0.21 F0 FibroTest – 0.80

Case Report Fibrotest 0.75-1.00 F4 0.73-0.74 F3-F4 0.59-0.72 F3 Equivalent METAVIR 0.75-1.00 F4 0.73-0.74 F3-F4 0.59-0.72 F3 0.49-0.58 F2 0.32-0.48 F1-F2 0.28-0.31 F1 0.22-0.27 F0-F1 0.00-0.21 F0 Alpha-2 macroglobulin Total Bilirubin Gamma GT Apolipoprotein A1 Haptoglobin Imbert-Bismuth et al. Lancet 2001; 357: 2069-75

Case Report – Question 2 FibroScan® and Fibrotest 3/6 months later ? What should we propose ? FibroScan® and Fibrotest 3/6 months later ? Liver biopsy ? Start new treatment immediately ?

Case Report Platelets 181 G/L PT 90 % ALT 133 IU/L AST 88 IU/L GGT 130 IU/L BMI 30 IU/L July / 2011

Case Report July / 2011 FibroScan® – 12.0 kPa / 1.2 / 100% FibroTest – 0.78

Case Report – Liver Biopsy Liver fragment – 20 mm and 12 portal tracts PT CV No difference in comparison with previous liver biopsy L.B: STEATOHEPATITIS + Hep C Metavir A0F1

Case Report FibroTest (n=8524) False Positives False Negatives Hemolysis Haptoglobin < 0.30 g/l Gilbert Bilirubin >17 µmol/l GGT< 30 UI/l Sepsis False Positives False Negatives Inflammation Haptoglobin > 2.0g/l Poynard et al. Clin Chem 2004; 8: 1344-55

Case Report FibroScan® (n=13 369) Obesity (BMI > 30) Limited operator experience Female Age > 52 ys Diabetes Hypertension Limitations Castera et al. Hepatology 2010;51: 828-35

STEATOSIS AND LIVER STIFFNESS P < 0.001 6.2 8.5 Nao tem impacto negativo na performance diagnostica Cardoso et al [abstract]. Hepatology International 2010

STEATOSIS DETECTION USING CAP Beaugrand et at. JVH 2011

STEATOSIS DETECTION USING CAP T = 236 dB/m, Se=0.83, Sp=0.73 T = 255 dB/m, Se=0.94, Sp=0.63 T = 282 dB/m, Se=0.95, Sp=1 Cardoso et al, AASLD 2010

Case Report Take-Home Messages FibroScan® and some serum markers are good tools for non invasive evaluation of liver fibrosis and can avoid liver biopsy in many cases. However discordance can occurs in 25% 10% of the discordances do not have an explanation Liver biopsy persist as the best standart for these cases

Case Report Fibrotest 0.75-1.00 F4 0.73-0.74 F3-F4 0.59-0.72 F3 Equivalent METAVIR 0.75-1.00 F4 0.73-0.74 F3-F4 0.59-0.72 F3 0.49-0.58 F2 0.32-0.48 F1-F2 0.28-0.31 F1 0.22-0.27 F0-F1 0.00-0.21 F0 Alpha-2 macroglobulin Total Bilirubin Gamma GT Apolipoprotein A1 Haptoglobin Imbert-Bismuth et al. Lancet 2001; 357: 2069-75

Castera et al, J Hepatol 2008; 48: 835-47 11/04/2017 Case Report 10 validated measures Success rate > 60% Results are expressed in kPa. The median Only procedures with 10 validated measurements and a success rate of at least 60% and a IQR < 30% of the median value are considered reliable. 11.2 0.9 14.6 IQR < 30% median Castera et al, J Hepatol 2008; 48: 835-47 24